Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors
A randomized trial is underway to evaluate surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors.
Therapeutic Area
Therapeutic area intelligence for Neuroendocrine Tumors with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.